'No Surprise' Says Vertex As NICE Fails To Recommend Orkambi In CF
This article was originally published in Scrip
Executive Summary
Vertex Pharmaceuticals Inc. says it is "not surprised" that NICE has issued draft guidance not recommending Orkambi (lumacaftor/ivacaftor) for use on the NHS in England.
You may also be interested in...
Scotland Fails To Recommend Orkambi But 'New Medicines Fund' Should Enable Access
The Scottish Medicines Consortium (SMC) on May 9 published advice mirroring that of its neighbor NICE failing to recommend the use of Vertex's Orkambi on the UK's NHS for the treatment of cystic fibrosis. This comes despite positive reimbursement decisions in other European countries. However, Scotland's New Medicines Fund should ensure there is a route available for patients to access the medicine, Vertex believes.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.